OF THE
TIMES





"enters certain cell lines with increased efficiency and evades antibody-mediated neutralization. In summary, A.30 exhibits a cell line preference not observed for other viral variants and efficiently evades neutralization by antibodies elicited by ChAdOx1 nCoV-19 [AstraZeneca] or BNT162b2 [Pfizer] vaccination."The variant also proved to be resistant to monoclonal drug Bamlanivimab, which is used for Covid-19 treatment, but was vulnerable to a cocktail of Bamlanivimab and Etesevimab.
Comment: It's not just vaccines they'll want to use these patches for...